Skip to main content
Equibles
OTLC logo

OTLC · Oncotelic Therapeutics, Inc. · Executive Compensation

Track OTLC — free

Use OTLC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OTLC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.02 0.00 (-4.86%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing.”
View the 10-Q filed Aug 13, 2026
Market Cap
$9.15M
Shares
457.51M
Volume · Oct 20 227.04K Avg daily vol (3M) 311.29K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Fatih Uckun, MD, Ph. D Resigned 2023-03-02

Leadership

Key facts CIK 908259 CUSIP 628341109 Visit website Investor relations